Development and validation of a novel prognostic index for mantle cell lymphoma integrating TP53 mutations ( MIPI53 )
British Journal of Haematology · 2026-06 · 208 (6) · 2004-2015
DOI: 10.1111/bjh.70535 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift British Journal of Haematology, online erschienen am 14.05.2026. Verfasst von Miguel Bastos-Boente und 26 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Department, Hospital Universitario de Salamanca (HUS-IBSAL), CIBERONC, and Centro de Investigación del Cáncer de Salamanca-IBMCC (CSIC-Uni…. Hauptthemen laut MEDLINE: Lymphoma, Mantle-Cell, Mutation, Tumor Suppressor Protein p53. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: Junta de Castilla y León, Fundació la Marató de TV3, Leukemia and Lymphoma Society.
Abstract (Originalsprache)
Mantle cell lymphoma (MCL) is a clinically heterogeneous disease with varying treatment responses and outcomes. Despite the utility of the Mantle Cell Lymphoma International Prognostic Index (MIPI), its predictive capacity can be enhanced by integrating genetic markers such as TP53 mutations. We analysed 143 newly diagnosed MCL patients from a real‐world cohort, assessing TP53 mutational status, clinical and biological markers. We developed the MIPI53 index by incorporating TP53 mutations, lactate dehydrogenase (LDH), Eastern Cooperative Oncology Group (ECOG) status and age. Internal validation was performed via bootstrapping, and external validation was conducted with data from the fondazione Italiana Linfomi (FIL) MCL0208 trial. Patients were stratified into low‐, intermediate‐ and high‐risk groups, showing significant differences in 5‐year progression‐free survival (PFS) (83.1%, 35.4% and 12.0%, respectively; p < 0.0001) and 5‐year overall survival (OS) (92.1%, 80.5% and 33.8%, respectively; p < 0.0001). External validation confirmed the robustness of the model (c‐index: 0.732; akaike information criterion, AIC: 296.2 according to OS). A simplified version (sMIPI53) was developed, maintaining high predictive accuracy in both training (c‐index: 0.819; AIC: 404.5) and external cohort (c‐index: 0.730; AIC: 296.7). The MIPI53 index effectively stratifies MCL patients into prognostic groups by integrating genetic and clinical variables to enhance outcome prediction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hematology Department, Hospital Universitario de Salamanca (HUS-IBSAL), CIBERONC, and Centro de Investigación del Cáncer de Salamanca-IBMCC (CSIC-Universidad de Salamanca), Salamanca, Spain.
- Dipartimento di Biotecnologie Molecolari e Scienze per la Salute, Università de Torino, Ematologia Universitaria Città della Salute e della Scienza di Torino, Torino, Italy.
- Fondazione Italiana Linfomi (FIL), Alessandria, Italy.
- Division of Hematology, Department of Translational Medicine, Università del Piemonte Orientale, Novara, Italy.
- Ematologia, Spedali Civili di Brescia, Brescia, Italy.
- SC Ematologia, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy.
ORCID-Profile: Miguel Bastos-Boente, Alejandro Medina-Herrera, Almudena Navarro-Bailón, Simone Ferrero, María Eugenia Sarasquete, Cristina Jiménez, María García-Álvarez, Ana Balanzategui, Ricardo Moia, Carola Boccomini, Maria Gomes da Silva, Óscar Blanco, Almudena Cabero, Marco Ladetto, Ramón García-Sanz, Norma C Gutiérrez, Alejandro Martín García-Sancho, Miguel Alcoceba
Förderung
- Junta de Castilla y León
- Fundació la Marató de TV3
- Leukemia and Lymphoma Society
- Ministero della Salute
- Instituto de Salud Carlos III
Zitieren
APA
Bastos-Boente, M., Medina-Herrera, A., Navarro-Bailón, A., Ferrero, S., Sarasquete, M. E., Jiménez, C., García-Álvarez, M., Antón, A., Balanzategui, A., Moia, R., Re, A., Boccomini, C., Balzarotti, M., Zilioli, V. R., da Silva, M. G., Díaz-Gálvez, F. J., González-Mena, B., Peñarrubia, M. J., Fernández-Ferrero, S., …, & Alcoceba, M. (2026). Development and validation of a novel prognostic index for mantle cell lymphoma integrating TP53 mutations ( MIPI53 ). British Journal of Haematology, 208(6), 2004-2015. https://doi.org/10.1111/bjh.70535
Vancouver
Bastos-Boente M, Medina-Herrera A, Navarro-Bailón A, Ferrero S, Sarasquete ME, Jiménez C, et al. Development and validation of a novel prognostic index for mantle cell lymphoma integrating TP53 mutations ( MIPI53 ). British Journal of Haematology. 2026;208(6):2004-2015. doi:10.1111/bjh.70535
BibTeX
@article{BastosBoente2026,
author = {Bastos-Boente, Miguel and Medina-Herrera, Alejandro and Navarro-Bailón, Almudena and Ferrero, Simone and Sarasquete, María Eugenia and Jiménez, Cristina and García-Álvarez, María and Antón, Alicia and Balanzategui, Ana and Moia, Ricardo and Re, Alessandro and Boccomini, Carola and Balzarotti, Monica and Zilioli, Vittorio Ruggero and da Silva, Maria Gomes and Díaz-Gálvez, Francisco Javier and González-Mena, Beatriz and Peñarrubia, María Jesús and Fernández-Ferrero, Silvia and de Ramón, Cristina and Blanco, Óscar and Cabero, Almudena and Ladetto, Marco and García-Sanz, Ramón and Gutiérrez, Norma C and Martín García-Sancho, Alejandro and Alcoceba, Miguel},
title = {Development and validation of a novel prognostic index for mantle cell lymphoma integrating TP53 mutations ( MIPI53 )},
journal = {British Journal of Haematology},
year = {2026},
volume = {208},
number = {6},
pages = {2004--2015},
doi = {10.1111/bjh.70535}
}
EUVIMED